Comprehensive Medication Monitoring on Heart Failure Patient Outcomes

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to evaluate the clinical utility of comprehensive medication monitoring using the Patient Medication Profile to improve heart failure patient medication therapy and associated outcomes relative to usual care in a hospital setting.

Clinical Trial Description

Congestive heart failure has an exceptionally high rate of hospital admission and is responsible for more re-admissions (23.5% at 30 days) in the United States than the 2nd and 3rd leading causes combined. Inadequate medication reconciliation both on admission and discharge from the hospital is a significant cause of medical error. In one study of cardiovascular patients, 44% believed they were taking a medication they were not, and 96% were unable to recall at least one medication they were taking. In the same study patients omitted on average 6.8 medications from their medication list. Medication optimization through improved adherence and reconciled medical records has been postulated to significantly improve admission and 30-day hospital readmission rates.

Sano has developed a blood-based comprehensive medication monitoring tool that identifies and quantitates 235 prescription drugs and drug metabolites. It does not detect illicit drugs. This tool, which produces an output report designated the 'Patient Medication Profile', is designed to be used with clinical decision support to improve medication adherence, reduce medication errors, and optimize medication therapy. For heart failure patients, the investigators hypothesize that deploying the Patient Medication Profile with clinical decision support at key points of treatment intervention will A) improve medication adherence, B) identify and reconcile significant discrepancies in the medication list, C) result in reduced hospital admissions, and D) result in better overall patient outcomes. These outcome expectations are relative to usual care for heart failure patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03519477
Study type	Interventional
Source	Precera Bioscience, Inc.
Contact
Status	Withdrawn
Phase	N/A
Start date	September 2018
Completion date	January 21, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03727646` - Nicotinamide Riboside in LVAD Recipients	Early Phase 1
Recruiting	`NCT05596760` - Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers	N/A
Recruiting	`NCT05227872` - PVF in Decongestion of Heart Failure
Recruiting	`NCT05543720` - Evaluation of Nurse-led Integrated Care of Complex Patients Facilitated By Telemonitoring: The SMaRT Study	N/A
Completed	`NCT04572425` - Virtual Reality for Pain Management in Advanced Heart Failure	N/A
Recruiting	`NCT03202329` - Evaluation of Post-operative, Nurse-based Heart Failure Care in Non-cardiac Surgery	N/A
Recruiting	`NCT03830957` - Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker	N/A
Recruiting	`NCT02672618` - Clinical Research to Explore Manifestations of Heart Failure Using Infrared Thermal Imaging Technology	N/A
Recruiting	`NCT04179643` - NAN-101 in Patients With Class III Heart Failure	Phase 1
Completed	`NCT04129658` - Heart Failure in Southern Sweden
Not yet recruiting	`NCT05591443` - Artificial Intelligence and Smart Wearable Technologies for Early Detection of Acute Heart Failure
Completed	`NCT03387813` - Hemodynamic-GUIDEd Management of Heart Failure	N/A
Completed	`NCT03187470` - Left Ventricular Dyssynchrony in Multipole Pacing	N/A
Completed	`NCT04628325` - Effects of Furosemide Plus Small HSS in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)	Phase 3
Completed	`NCT03385837` - Activity Level and Barriers to Participate of Cardiac Rehabilitation in Advanced Heart Failure Patients
Completed	`NCT04281849` - Balance, Aerobic Capacity, Mobility and Strength in Patients Hospitalized for Heart Failure (BAMS-HF) Program	N/A
Not yet recruiting	`NCT04403659` - Telemonitoring of Patients Admitted in Hospital at Home With Acute Decompensated Heart Failure - Pilot Study	N/A
Terminated	`NCT04142788` - RELieving Increasing oEdema Due to Heart Failure	Phase 4
Active, not recruiting	`NCT04283994` - Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2)	N/A
Completed	`NCT03722069` - Dietary Sodium Intake in Acute Heart Failure	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.